Tokai Pharmaceuticals Inc  

(Public, NASDAQ:TKAI)   Watch this stock  
Find more results for Joseph McBride
-0.31 (-2.27%)
Jul 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.11 - 13.62
52 week 9.67 - 30.00
Open 13.51
Vol / Avg. 91,134.00/153,415.00
Mkt cap 305.72M
P/E     -
Div/yield     -
EPS -1.43
Shares 22.41M
Beta     -
Inst. own 28%
Jun 24, 2015
Tokai Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 10, 2015
Tokai Pharmaceuticals Inc at William Blair Annual Growth Stock Conference - Webcast
Jun 4, 2015
Tokai Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 13, 2015
Tokai Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 12, 2015
Q1 2015 Tokai Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.04% -33.27%
Return on average equity -54.72% -96.60%
Employees 17 -
CDP Score - -


255 State St Fl 6
BOSTON, MA 02109-2617
United States - Map
+1-617-2254348 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate galeterone is a multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC), whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone, known as ARMOR2 trial, for the treatment of multiple CRPC populations.

Officers and directors

Lee H. Kalowski Chief Financial Officer
Age: 34
Bio & Compensation  - Reuters
John S. McBride Chief Operating Officer
Age: 63
Bio & Compensation  - Reuters
Gerald E. Quirk Esq. Executive Vice President - Business Operations, General Counsel
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Head - Research and Development and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Jodie Pope Morrison President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
Cheryl L. Cohen Director
Age: 49
Bio & Compensation  - Reuters
Timothy Joseph Barberich Independent Director
Age: 67
Bio & Compensation  - Reuters
Stephen Buckley Jr. Independent Director
Age: 65
Bio & Compensation  - Reuters
David A. Kessler M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters